Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with <i>BRAF</i> V600E/K-mutant melanoma in the COMBAT trial

Caroline Robert, Jean‐Jacques Grob, Caroline Dutriaux et al.|Cancer Research|2018

Cited by 1